SRR2712420
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.300
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- E2F_TARGETS+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
- PEROXISOME+0.200
- SPERMATOGENESIS+0.200
- COMPLEMENT+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- TGF_BETA_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.300
- MYOGENESIS-0.300
- UV_RESPONSE_DN-0.300
- ADIPOGENESIS-0.200
- COAGULATION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A08I-01A-11R-A00Z-07 | — | C | 0.867 |
| 2 | SRR2932831 | — | — | 0.831 |
| 3 | 1f57edd1-3bc9-4eaf-8045-8984d5c7f148 | — | — | 0.828 |
| 4 | R17 | — | — | 0.800 |
| 5 | ULC0583T_S75 | — | cohortA1 | 0.799 |
| 6 | s0122145 | — | — | 0.774 |
| 7 | TCGA-55-A4DF-01A-11R-A24H-07 | — | cohortA3 | 0.761 |
| 8 | ERR2208913 | — | — | 0.761 |
| 9 | 1692105e-13d3-45ca-ab70-e6aed396c8c0 | — | — | 0.746 |
| 10 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |